Skip to content

OnyxBiotech News

Subscribe About Onyx
Cell & Gene Leaders Live Sunday 15 November 2026 · The Shard (Shangri-La), London · One-day summit for cell & gene therapy leaders Sunday 15 November 2026 · The Shard (Shangri-La), London Get tickets → London Life Sciences Week Guide The unofficial London Life Sciences Week Guide, published by Onyx Newsroom · Every event 15–19 November 2026 Every event 15–19 November 2026 · Published by Onyx Newsroom Plan your week →
Press Release

Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines

Aspect Biosystems announced receiving a $79 million investment from the Government of Canada, supporting a $280 million, multi-year project to accelerate its pipeline of bioengineered cellular medicines for serious metabolic and endocrine diseases.

Press release. Published as received.

Table of Contents
Corporate Overview

Aspect Biosystems

About Aspect Biosystems ▼
Aspect Biosystems is a biotechnology company pioneering development of regenerative medicine designed to restore or supplement biological function and deliver curative therapies. Aspect applies its full-stack tissue therapeutic platform integrating proprietary AI-powered bioprinting technology, therapeutic cells, hypoimmune cell engineering, and advanced biomaterials across endocrine and metabolic diseases including diabetes and rare endocrine disorders. For more information, visit aspectbiosystems.com.
Media Contact

Natalie Korenic

Aspect Biosystems

Apr 2, 2026

Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered cellular medicines

VANCOUVER, BC – April 2, 2026 – Aspect Biosystems, a biotechnology company pioneering a novel category of regenerative medicine, today announced receiving a $79 million investment from the Government of Canada. The funding supports a $280 million, multi-year project to accelerate the advancement of Aspect’s pipeline of bioengineered cellular medicines for serious metabolic and endocrine diseases. The project will significantly enhance Aspect’s clinical development capabilities and strengthen the company’s vertically integrated platform for development and biomanufacturing of advanced cellular medicines. This builds upon a previously announced $200 million co-investment with the Government of Canada and the Province of British Columbia in 2024.

Aspect develops disease-modifying therapies designed to restore or supplement biological functions in the body. The company applies its full-stack platform, combining proprietary AI-powered bioprinting technology and hypoimmune cell engineering, to create scalable bioengineered cellular medicines.

“This investment from the Government of Canada is a powerful vote of confidence and adds to significant momentum at Aspect as we advance our bioengineered cellular medicines towards patient impact,” said Tamer Mohamed, CEO of Aspect Biosystems.
“Today’s announcement with Aspect Biosystems is an example of Canada’s leadership in scientific innovation and advanced biomanufacturing,” said the Honourable Mélanie Joly, Minister of Industry.

This partnership builds on recent momentum at Aspect, including entering a new phase of its partnership with Novo Nordisk earlier this year. It also follows a US$115 million Series B in 2025 and a $200 million co-investment with the Government of Canada and Province of British Columbia in 2024.

Source: Aspect Biosystems Press Release

Coming up: Cell & Gene Leaders Live, Sun 15 Nov at The Shard · London Life Sciences Week Guide, 15–19 Nov 2026 ·

Comments